Table 1 Characterization of the octreotide(−)/radtech(+) livers, including results from the nNUFTI analyses
Patient | Time of diagnosis (years) | Image modality | Tumour type | Number of metastases | nThI | PPV |
|---|---|---|---|---|---|---|
42F | 0.0 | CT | HCC, carcinoid(ECL) | Multiple | 0.748 | 1.0 |
32F | 0.3 | US | Midgut carcinoid | Three | 0.743 | 1.0 |
41F | −0.8 | CT | Midgut carcinoid | Single | 0.718 | 1.0 |
55F | −0.4 | CT | NET, origin unknown | Multiple | 0.697 | 1.0 |
84M | 1.0 | CT | Midgut carcinoid | Multiple | 0.659 | 0.50 |
25M | 1.5 | CT | Medullary thyroid cancer | Single | 0.655 | 0.50 |
43 M | 1.4 | US, CT | Midgut carcinoid | Four | 0.642 | 0.35 |
90M | 2.4 | CT | Medullary thyroid cancer | Single | 0.641 | 0.38 |
30F | 2.7 | CT | Endocrine pancreatic | Single | 0.637 | 0.38 |
109F | 1.5 | CT | Lung carcinoid | Single | 0.621 | 0.32 |
111F | 2.6 | CT | Midgut carcinoid | Two | 0.619 | 0.33 |
104F | 0.2 | US | Midgut carcinoid, cervix cancer | Multiple | 0.599 | 0.27 |
103M | −0.1 | CT | Midgut carcinoid | Multiple | 0.581 | 0.26 |